Autonomix Medical, Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-14$0.53 RISE2026-05-19$0.28 PEAK2026-05-26$0.42 132d | -46.4% 125d | Missed | Missed | — | — | +47.2% 7d | Missed |
DROP2025-10-09$1.26 RISE2026-02-05$0.35 PEAK2026-03-18$0.46 160d | -71.9% 119d | Missed | Missed | — | — | +29.7% 41d | Missed |
DROP2025-06-27$2.01 RISE2025-09-25$1.03 PEAK2025-10-09$1.26 104d | -48.8% 90d | Missed | Missed | — | — | +22.3% 14d | Missed |
DROP2025-04-29$2.53 RISE2025-08-22$1.01 PEAK2025-10-09$1.26 163d | -60.1% 115d | Missed | Missed | — | — | +24.8% 48d | Missed |
DROP2025-04-29$2.53 RISE2025-08-21$1.01 PEAK2025-10-09$1.26 163d | -60.1% 114d | Missed | Missed | — | — | +24.8% 49d | Missed |
DROP2025-02-24$2.98 RISE2025-06-18$1.20 PEAK2025-06-27$2.01 123d | -59.7% 114d | Missed | Missed | — | — | +67.5% 9d | Missed |
DROP2024-11-25$6.33 RISE2025-04-08$1.61 PEAK2025-04-29$2.53 155d | -74.6% 134d | Missed | Missed | — | — | +57.5% 21d | Missed |
DROP2024-09-04$18.24 RISE2025-01-13$2.64 PEAK2025-01-22$3.21 140d | -85.5% 131d | Missed | Missed | — | — | +21.6% 9d | Missed |
DROP2024-04-26$67.20 RISE2024-08-29$11.48 PEAK2024-09-04$18.24 131d | -82.9% 125d | Missed | Missed | — | — | +58.9% 6d | Missed |
DROP2024-02-28$86.80 RISE2024-07-09$10.64 PEAK2024-07-22$30.80 145d | -87.7% 132d | Missed | Missed | — | — | +189.5% 13d | Missed |
DROP2024-02-28$86.80 RISE2024-07-08$10.64 PEAK2024-07-22$30.80 145d | -87.7% 131d | Missed | Missed | — | — | +189.5% 14d | Missed |
DROP2024-02-02$118.80 RISE2024-04-09$53.20 PEAK2024-04-26$67.20 84d | -55.2% 67d | Missed | Missed | — | — | +26.3% 17d | Missed |
No scored news yet for a sentiment trend.
The trading volume of these stocks is deviating from the norm in today's session.
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expected Q4 results, with adjusted earnings of 11 cents per share and revenue of $185.25 million. GCL, PETZ, WOK, MEHA, HAO, TDIC, FEED, KELYA, and AMC were among the top gainers, while RUBI, AMIX, IPW, ANVS, and WGRX were among the top losers in pre-market trading.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall Patent strengthens intellectual property foundation for next-generation neuromodulation technologies THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO)
Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wallPatent strengthens intellectual property foundation for next-generation neuromodulation
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France. T
Autonomix Medical Inc:Autonomix Medical announces abstract acceptance at Digestive Disease Week 2026 showcasing long-term data in pancreatic cancer pain mitigation....
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), being held May 2–5, 2026, in Chicago, IL an
THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the European Conference on Interventional Oncology (ECIO) 2026 being held April 26 – 30, 2026 in Basel C
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its abstract titled, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” has been selected as a Featured Abstract for podium presentation at the Society of Interventional Radiology (SIR) 2026 A
THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA ’26 on Tuesday, March 17, 2026 at 9:15 AM PT. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of
https://patentcenter.uspto.gov/applications/18079361/ifw/docs
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026. The presentation will be delivered
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis
CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. As part of the segment, Mr. Hauser discusses Autonomix’s
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AMIX | +8.11% | -1.48% | -27.27% | -75.38% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +5.14% | +4.24% | -23.83% | -88.07% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-02-11 | -0.46 | -0.36 | +21.74% |
| 2025-11-12 | -1.50 | -1.38 | +8.00% |
| 2025-08-13 | -0.98 | -1.07 | -9.18% |
| 2025-05-29 | -1.24 | -0.74 | +40.08% |
| 2025-02-13 | -2.40 | -1.46 | +39.17% |
| 2024-11-08 | — | -2.47 | — |